This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two additional groups presenting moderate to high yields up to 8%. The selections aim to provide conservative dividend growth investing options with stable, long-term passive income. The author, Financially Free Investor, uses a unique approach focused on lower drawdowns, consistent income, and market-beating growth, supported by exclusive portfolios for subscribers.
Abbott received FDA De Novo authorization for Libre Duo 10 Day, the first wearable device that continuously monitors glucose and detects rising ketone levels, which can signal diabetic ketoacidosis. This regulatory milestone sets Abbott apart in diab...
Abbott has received CE Mark approval for its Amulet 360 Left Atrial Appendage Occluder, a next-generation device designed to reduce stroke risk in patients with atrial fibrillation (AFib) by sealing the heart's left atrial appendage (LAA). The device...
Abbott has received FDA authorization for its Libre Duo 10 Day system, the world's first biowearable device that continuously monitors both glucose and ketone levels. This innovation helps people with diabetes detect rising ketones early, which can p...
Retirees choosing between Schwab U.S. Dividend Equity ETF (SCHD) and Vanguard Real Estate ETF (VNQ) face a clear divergence due to the current high interest rate environment. SCHD, focused on dividend-paying companies with strong cash flow, has outpe...
